Brief: Puma Biotechnology’s Nerlynx Included In Two Important NCCN Clinical Practice Guideline Updates
12/01/2022 21:26
Jan 12 (Reuters) - Puma Biotechnology Inc PBYI.O :
* PUMA BIOTECHNOLOGY’S NERLYNX® INCLUDED IN TWO IMPORTANT
NCCN
CLINICAL PRACTICE GUIDELINE UPDATES FOR THE TREATMENT OF BREAST
CANCER
Source text for Eikon: ID:nBw31HXTYa
Further company coverage: PBYI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Puma Biotechnology
See all newsBrief: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2